JMP Securities analyst Jason Butler reiterated a Buy rating on Precigen (PGEN – Research Report) today and set a price target of $14.00. The company’s shares opened today at $1.28.
According to TipRanks, Butler is an analyst with an average return of -5.2% and a 41.57% success rate. Butler covers the Healthcare sector, focusing on stocks such as Cormedix, Precigen, and Aquestive Therapeutics.
Currently, the analyst consensus on Precigen is a Moderate Buy with an average price target of $10.00.
See today’s best-performing stocks on TipRanks >>
Based on Precigen’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $22.18 million. In comparison, last year the company earned a revenue of $24.22 million and had a GAAP net loss of $25.03 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Read More on PGEN:
